Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PT-141

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

bremelanotide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Melanocortin receptors, melanotropic peptides and penile erection.
Penile erection is a complex physiologic event resulting from the interactions of the nervous system on a highly specialized… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.
INTRODUCTION Melanocortins affect multiple physiological responses, including sexual behaviors. Bremelanotide is a synthetic… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
2005
2005
Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.
OBJECTIVES To evaluate the safety and pharmacodynamic effect of co-administration of subtherapeutic doses of PT-141, a cyclic… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients…
PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following intranasal administration in healthy male subjects and… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an…
PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following subcutaneous administration to healthy male subjects… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist.
Disorders of sexual desire affect an estimated 30% of women in North America and Europe, with etiologies based on interpersonal… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2004
2004
Evaluation of the Safety, Pharmacokinetics and Pharmacodynamic Effects of Subcutaneously Administered PT-141, a Melanocortin Receptor Agonist, in Healthy Male Subjects and in Patients With an…
 
Is this relevant?
2004
2004
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… Expand
Is this relevant?
2004
2004
Statins: Target audience
  • S. Frantz
  • Nature Reviews Drug Discovery
  • 2004
    • Corpus ID: 7107118
The considerable success of phosphodiesterase 5 inhibitors, such as sildenafil (Viagra; Pfizer), in the treatment of erectile… Expand
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PT‐141: A Melanocortin Agonist for the Treatment of Sexual Dysfunction
Abstract: PT‐141, a synthetic peptide analogue of α‐MSH, is an agonist at melanocortin receptors including the MC3R and MC4R… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE